Advertisements



Acasti Pharma to seek FDA guidance prior to unblinding TRILOGY 2 data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020

Acasti Pharma announces investigation into Phase 3 TRILOGY 1 results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 10th, 2020

Acasti Pharma announces results from TRILOGY 1 Phase 3 trial of CaPre

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 13th, 2020

Acasti Pharma reports last patient visit in TRILOGY 1 Phase 3 trial of CaPre

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 26th, 2019

Acasti Pharma releases preliminary animal data on CaPres mechanism of action

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 18th, 2019

Acasti Pharma says on track to report results fror TRILOGY 2 in January

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 13th, 2019

Acasti Pharma says on track to report results fror TRILOGY 1 in December

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 13th, 2019

Acasti Pharma expects topline results for TRILOGY 1 in December

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 14th, 2019

Short Sellers Seek Direction on Big Pharma

The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed......»»

Category: blogSource: 247wallstJun 26th, 2019

Acasti Pharma "on track" to report topline results for TRILOGY 1 in December

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 26th, 2019

Acasti Pharma Provides Fiscal 2019 Year-End Business Update

Both Phase 3 TRILOGY studies at 100% randomization >60% of patients have completed the 6-month trial Release of topline results r.....»»

Category: earningsSource: benzingaJun 26th, 2019

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at 110 clinical sites as of .....»»

Category: earningsSource: benzingaJun 27th, 2018

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019

TRILOGY studies surpass 50% enrollment and continue on track to complete enrollment in 2018 Awarded composition-of-matter patent .....»»

Category: earningsSource: benzingaAug 14th, 2018

Acasti Pharma achieves enrollment targets for TRILOGY trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2018

Genfit says unblinding of RESOLVE-IT data delayed for FDA feedback

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 21st, 2020

Hannon Armstrong sees 2020 core EPS above prior guidance midpoint $1.43

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 20th, 2020

Apple Experts React To iPhone Maker"s Revenue Warning, Coronavirus Threat

Shares of Apple Inc. (NASDAQ: AAPL) were trading lower by 2% early Tuesday morning after the iPhone maker said it doesn't expect to meet its prior fiscal second-quarter revenue guidance of $63 to $67 .....»»

Category: blogSource: benzingaFeb 18th, 2020

Acasti Pharma price target lowered to $3 from $6 at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 18th, 2020

New data provides guidance for demonstrating corporate character

2020 kicked off amid a flurry of business dialogue about profit and purpose, shareholders and stakeholders, and young consumers imploring corporations to be a force for good. From the Business Roundtable’s statement of purpose to BlackRock’s sta.....»»

Category: topSource: bizjournalsFeb 17th, 2020

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

LAVAL, Québec, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commer.....»»

Category: earningsSource: benzingaFeb 14th, 2020

Acasti Pharma sees cash sufficient through at least December 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020